Vancomycin combined with piperacillin/tazobactam is a common clinical treatment regimen. This low-cost regimen covers both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas adaceae, and it is commonly used in patients in intensive care units, and it plays a key role in the first-line treatment of patients with severe infections such as acute sepsis. However, multiple clinical studies have shown this combination regimen may increase the risk of acute kidney injury, resulting in treatment failure, prolonged hospital stay, and even the life-threatening of patients in severe cases. Therefore, this study reviewed the epidemiology, pathogenesis, prevention and treatment of acute kidney injury induced by vancomycin combined with piperacillin/tazobactam, in order to provide evidence for the safe use of vancomycin and piperacillin/tazobactam in clinic.

1.Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011, 52(3): e18-55. DOI: 10.1093/cid/ciq146.

2.Casenaz A, Piroth L, Labattut L, et al. Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence, a 10-year study[J]. J Infect, 2022, 85(5): 492-498. DOI: 10.1016/j.jinf.2022.07.009.

3.Tanaka K, Nakamura T, Imai S, et al. The use of broad-spectrum antibiotics reduces the incidence of surgical site infection after pancreatoduodenectomy[J]. Surg Today, 2018, 48(9): 825-834. DOI: 10.1007/s00595-018-1658-3.

4.Ouyang W, Xue H, Chen Y, et al. Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China[J]. Int J Antimicrob Agents, 2016, 47(3): 210-216. DOI: 10.1016/j.ijantimicag.2015.12.019.

5.Ziglam HM, Gelly K, Olver W. A survey of the management of neutropenic fever in oncology units in the UK[J]. Int J Antimicrob Agents, 2007, 29(4): 430-433. DOI: 10.1016/j.ijantimicag.2006.12.009.

6.Carreno J, Smiraglia T, Hunter C, et al. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy[J]. Int J Antimicrob Agents, 2018, 52(5): 643-650. DOI: 10.1016/j.ijantimicag.2018.08.001.

7.高璇, 李静, 李智平. 住院儿童单独使用万古霉素或联合哌拉西林/他唑巴坦治疗后的肾毒性比较[J]. 复旦学报(医学版), 2015, 42(6): 743-748. [Gao X, Li J, Li ZP. Comparison of nephrotoxicity in hospitalized children treated with vancomycin alone or in combination with piperacillin/tazobactam[J]. Fudan University Journal of Medical Sciences, 2015, 42(6): 743-748.] DOI: 10.3969/j.issn.1672-8467.2015.06.009.

8.Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime[J]. Clin Infect Dis, 2017, 64(2): 116-123. DOI: 10.1093/cid/ciw709.

9.Kunming P, Can C, Zhangzhang C, et al. Vancomycin associated acute kidney injury: a longitudinal study in China[J]. Front Pharmacol, 2021, 12: 632107. DOI: 10.3389/fphar.2021.632107.

10.Tang Girdwood S, Hasson D, Caldwell JT, et al. Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury[J]. J Antimicrob Chemother, 2023, 78(2): 478-487. DOI: 10.1093/jac/dkac416.

11.Blair K, Covington EW. Incidence and risk factors of acute kidney injury in patients receiving concomitant vancomycin and continuous-infusion piperacillin/tazobactam: a retrospective cohort study[J]. Ann Pharmacother, 2020, 54(11): 1096-1101. DOI: 10.1177/1060028020921170.

12.Yamashita Y, Kawaguchi H, Yano T, et al. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: a retrospective study[J]. J Infect Chemother, 2021, 27(11): 1614-1620. DOI: 10.1016/j.jiac.2021.07.017.

13.Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study[J]. JAMA, 2005, 294(7): 813-818. DOI: 10.1001/jama.294.7.813.

14.Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis[J]. Crit Care, 2006, 10(3): R73. DOI: 10.1186/cc4915.

15.Thakar CV, Christianson A, Freyberg R, et al. Incidence and outcomes of acute kidney injury in intensive care units: a veterans administration study[J]. Crit Care Med, 2009, 37(9): 2552-2558. DOI: 10.1097/CCM.0b013 e3181a5906f.

16.Hoste EA, Kellum JA. RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality[J]. Crit Care Med, 2006, 34(7): 2016-2017. DOI: 10.1097/01.CCM.0000219374.43963.B5.

17.Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern[J]. Lancet, 2013, 382(9887): 170-179. DOI: 10.1016/S0140-6736(13)60647-9.

18.Silver SA, Long J, Zheng Y, et al. Cost of acute kidney injury in hospitalized patients[J]. J Hosp Med, 2017, 12(2): 70-76. DOI: 10.12788/jhm.2683.

19.Williams C, Hankinson C, McWilliam SJ, et al. Vancomycin-associated acute kidney injury epidemiology in children: a systematic review[J]. Arch Dis Child, 2022, 107(10): 947-954. DOI: 10.1136/archdischild-2021- 323429.

20.Kloprogge F, Hill LF, Booth J, et al. Revising pediatric vancomycin dosing accounting for nephrotoxicity in a pharmacokinetic-pharmacodynamic model[J]. Antimicrob Agents Chemother, 2019, 63(5): e00067-19. DOI: 10.1128/AAC.00067-19.

21.Hall RG 2nd, Yoo E, Faust A, et al. Impact of piperacillin/tazobactam on nephrotoxicity in patients with gram-negative bacteraemia[J]. Int J Antimicrob Agents, 2019, 53(3): 343-346. DOI: 10.1016/j.ijantimicag.2018.11.002.

22.Kadomura S, Takekuma Y, Sato Y, et al. Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study[J]. J Pharm Health Care Sci, 2019, 5: 13. DOI: 10.1186/s40780-019-0142-6.

23.Joyce EL, Kane-Gill SL, Priyanka P, et al. Piperacillin/tazobactam and antibiotic-associated acute kidney injury in critically ill children[J]. J Am Soc Nephrol, 2019, 30(11): 2243-2251. DOI: 10.1681/ASN.2018121223.

24.Jeon N, Staley B, Klinker KP, et al. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function[J]. Int J Antimicrob Agents, 2017, 50(1): 63-67. DOI: 10.1016/j.ijantimicag.2017.02.023.

25.Kalligeros M, Karageorgos SA, Shehadeh F, et al. The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: a systematic review and meta-analysis[J]. Antimicrob Agents Chemother, 2019, 63(12): e01572-19. DOI: 10.1128/AAC. 01572-19.

26.Holsen MR, Meaney CJ, Hassinger AB, et al. Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam[J]. Pediatr Crit Care Med, 2017, 18(12): e585-e591. DOI: 10.1097/PCC.0000000000001335.

27.O'Callaghan K, Hay K, Lavana J, et al. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: a retrospective cohort study[J]. Int J Antimicrob Agents, 2020, 56(1): 106010. DOI: 10.1016/j.ijantimicag.2020.106010.

28.Hammond DA, Smith MN, Painter JT, et al. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study[J]. Pharmacotherapy, 2016, 36(5): 463-471. DOI: 10.1002/phar.1738.

29.Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis[J]. Crit Care Med, 2018, 46(1): 12-20. DOI: 10.1097/CCM.0000000 000002769.

30.Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study[J]. Intensive Care Med, 2022, 48(9): 1144-1155. DOI: 10.1007/s00134-022-06811-0.

31.Rodrigo E, Suberviola B, Santibanez M, et al. Association between recurrence of acute kidney injury and mortality in intensive care unit patients with severe sepsis[J]. J Intensive Care, 2017, 5: 28. DOI: 10.1186/s40560-017-0225-0.

32.Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review[J]. Eur J Clin Pharmacol, 2012, 68(9): 1243-1255. DOI: 10.1007/s00228-012-1259-9.

33.Kan WC, Chen YC, Wu VC, et al. Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application[J]. Int J Mol Sci, 2022, 23(4): 2052. DOI: 10.3390/ijms23042052.

34.Lee HS, Kim SM, Jang JH, et al. Serum 5-hydroxyindoleacetic acid and ratio of 5-hydroxyindoleacetic acid to serotonin as metabolomics indicators for acute oxidative stress and inflammation in vancomycin-associated acute kidney injury[J]. Antioxidants (Basel), 2021, 10(6): 895. DOI: 10.3390/antiox10060895 .

35.Polderman KH, Girbes AR. Piperacillin-induced magnesium and potassium loss in intensive care unit patients[J]. Intensive Care Med, 2002, 28(4): 520-522. DOI: 10.1007/s00134-002-1244-3.

36.Pratt JA, Stricherz MK, Verghese PS, et al. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population[J]. Pediatr Blood Cancer, 2014, 61(2): 366-368. DOI: 10.1002/pbc.24720.

37.Kraleti S, Khatri N, Jarrett D. Piperacillin-tazobactam induced interstitial nephritis, hepatitis and serum sckness-like illness[J]. J Ark Med Soc, 2016, 112(14): 278-280. https://pubmed.ncbi.nlm.nih.gov/27434982/.

38.Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam[J]. Pharmacotherapy, 2014, 34(7): 670-676. DOI: 10.1002/phar.1442.

39.Komuro M, Maeda T, Kakuo H, et al. Inhibition of the renal excretion of tazobactam by piperacillin[J]. J Antimicrob Chemother, 1994, 34(4): 555-564. DOI: 10.1093/jac/34.4. 555.

40.Wen S, Wang C, Huo X, et al. JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats[J]. Toxicol Lett, 2018, 295: 195-204. DOI: 10.1016/j.toxlet.2018.06.1220.

41.Vallon V, Eraly SA, Rao SR, et al. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice[J]. Am J Physiol Renal Physiol, 2012, 302(10): F1293-1299. DOI: 10.1152/ajprenal.00013.2012.

42.Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients[J]. Clin Infect Dis, 2009, 49(4): 507-514. DOI: 10.1086/600884.

43.Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin[J]. Clin Pharmacol Ther, 2017, 102(3): 459-469. DOI: 10.1002/cpt.726.

44.熊祥樽, 田小燕, 张佳颖, 等. 烧伤患者万古霉素相关急性肾损伤调查及危险因素分析[J]. 药物流行病学杂志, 2019, 28(11): 740-744, 752. [Xiong XZ, Tian XY, Zhang JY, et al. Current situation survey and risk factors analysis of vancomycin-associated acute kidney injury in burn patients[J]. Chinese Journal of Pharmacoepidemiology, 2019, 28(11): 740-744, 752.] DOI: 10.19960/j.cnki.issn1005-0698.2019.11.009.

45.门鹏, 李慧博, 翟所迪. 万古霉素血药峰浓度与临床结局相关性的系统评价[J]. 药物流行病学杂志, 2015, 24(6): 328-331. [Men P, Li HB, Zhai SD, et al. Association between vancomycin serum peak concentrations and clinical outcomes: a systematic review[J]. Chinese Journal of Pharmacoepidemiology, 2015, 24(6): 328-331.] DOI: 10.19960/j.cnki.issn1005-0698.2015.06.002.

46.Avedissian SN, Pais G, Liu J, et al. The Pharmacodynamic-toxicodynamic relationship of AUC and Cmax in vancomycin-induced kidney injury in an animal model[J]. Antimicrob Agents Chemother, 2021, 65(3): e01945-20. DOI: 10.1128/AAC.01945-20.

47.Oda K, Hashiguchi Y, Katanoda T, et al. Lowered risk of nephrotoxicity through intervention against the combined use of vancomycin and tazobactam/piperacillin: a retrospective cohort study[J]. Microbiol Spectr, 2021, 9(1): e0035521. DOI: 10.1128/Spectrum.00355-21.

48.Balci C, Uzun O, Arici M, et al. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?[J]. Int J Antimicrob Agents, 2018, 52(2): 180-184. DOI: 10.1016/j.ijantimicag.2018.03.024.

49.Bellos I, Karageorgiou V, Pergialiotis V, et al. Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis[J]. Clin Microbiol Infect, 2020, 26(6): 696-705. DOI: 10.1016/j.cmi.2020.03.019.

50.Rutter WC, Cox JN, Martin CA, et al. Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime[J]. Antimicrob Agents Chemother, 2017, 61(2): e02089-16. DOI: 10.1128/aac.02089-16.

51.Liu K, Zhang Y, Xu X, et al. Comparative prevalence of acute kidney injury in chinese patients receiving vancomycin with concurrent β-lactam antibiotics: a retrospective cohort study[J]. Clin Ther, 2021, 43(10): e319-e351. DOI: 10.1016/j.clinthera.2021.08.008.

52.Rutter WC, Burgess DS. Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin[J]. Antimicrob Agents Chemother, 2018, 62(7): e00264-18. DOI: 10.1128/AAC.00264-18.

53.Downes KJ, Cowden C, Laskin BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children[J]. JAMA Pediatr, 2017, 171(12): e173219. DOI: 10.1001/jamapediatrics.2017.3219.

54.Schreier DJ, Kashani KB, Sakhuja A, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin[J]. Clin Infect Dis, 2019, 68(9): 1456-1462. DOI: 10.1093/cid/ciy724.

55.Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion[J]. J Clin Pharm Ther, 2015, 40(3): 259-265. DOI: 10.1111/jcpt.12270.

56.刘露, 吴知桂, 范清泽, 等. 万古霉素持续输注与间歇输注有效性与安全性比较的Meta分析[J]. 中国药房, 2020, 31(22): 2774-2780. [Liu L, Wu ZG, Fan QZ, et al. Efficacy and safety of vancomycin given by continuous infusion vs. intermittent infusion: a meta-analysis[J]. China Pharmacy, 2020, 31(22): 2774-2780.] DOI: 10.6039/j.issn. 1001-0408.2020.22.15.

57.Chongcharoenyanon T, Wacharachaisurapol N, Anugulruengkitt S, et al. Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients[J]. Int J Infect Dis, 2021, 108: 102-108. DOI: 10.1016/j.ijid.2021.05.044.

58.Rhodes NJ, Liu J, O'Donnell JN, et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis[J]. Crit Care Med, 2018, 46(2): 236-243. DOI: 10.1097/CCM.0000000000002836.

59.Muklewicz JD, Steuber TD, Edwards JD. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury[J]. Int J Antimicrob Agents, 2021, 57(1): 106234. DOI: 10.1016/j.ijantimicag.2020.106234.

60.Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant staphylococcus aureus infections: putting the safety of our patients first[J]. Clin Infect Dis, 2021, 72(9): 1497-1501. DOI: 10.1093/cid/ciaa1744.

61.Hambrick HR, Greco KF, Weller E, et al. Impact of decreasing vancomycin exposure on acute kidney injury in stem cell transplant recipients[J]. Infect Control Hosp Epidemiol, 2022, 43(10): 1375-1381. DOI: 10.1017/ice. 2021.454.

62.Hu B, Ye L, Li T, et al. Drug-induced kidney injury in Chinese critically ill pediatric patients[J]. Front Pharmacol, 2022, 13: 993923. DOI: 10.3389/fphar.2022.993923.

63.Griffin BR, Wendt L, Vaughan-Sarrazin M, et al. Nephrotoxin exposure and acute kidney injury in adults[J]. Clin J Am Soc Nephrol, 2023, 18(2): 163-172. DOI: 10.2215/CJN.0000000000000044.

64.Kim JY, Kim KY, Yee J, et al. Risk scoring system for vancomycin-associated acute kidney injury[J]. Front Pharmacol, 2022, 13: 815188. DOI: 10.3389/fphar.2022. 815188.

65.Hong TS, Briscese K, Yuan M, et al. Renoprotective effects of melatonin against vancomycin-related acute kidney injury in hospitalized patients: a retrospective cohort study[J]. Antimicrob Agents Chemother, 2021, 65(9): e0046221.DOI: 10.1128/AAC.00462-21.

66.Abbasi S, Bigharaz E, Farsaei S, et al. Could melatonin prevent vancomycin-induced nephrotoxicity in critically ill patients? A randomized, double-blinded controlled trial[J]. Caspian J Intern Med, 2023, 14(1): 76-82. DOI: 10.22088/cjim.14.1.76.

67.李娟, 何娟, 毛恩强, 等. 还原型谷胱甘肽对重症患者使用万古霉素致药物性肾损伤的保护作用[J]. 中华危重病急救医学, 2020, 32(7): 819-823. [Li J, He J, Mao EQ, et al. Protective effects of reduced glutathione on renal toxicity induced by vancomycin in critically ill patients[J]. Chinese Critical Care Medicine, 2020, 32(7): 819-823.] DOI: 10.3760/cma.j.cn121430-20200429-00326.

68.何娟, 毛恩强, 徐文筠, 等. 大剂量维生素C可显著降低重症患者万古霉素的肾毒性[J]. 中华危重病急救医学, 2020, 32(4): 468-472. [He J, Mao EQ, Xu WY, et al. High dose vitamin C significantly reduces the nephrotoxicity of vancomycin in critically ill patients[J]. Chinese Critical Care Medicine, 2020, 32(4): 468-472.] DOI: 10.3760/cma.j.cn121430-20200110-00083.

69.Khalili H, Rahmani H, Mohammadi M, et al. Intravenous magnesium sulfate for prevention of vancomycin plus piperacillin-tazobactam induced acute kidney injury in critically ill patients: an open-label, placebo-controlled, randomized clinical trial[J]. Daru, 2021, 29(2): 341-351. DOI: 10.1007/s40199-021-00411-x.

70.Wicklow BA, Ogborn MR, Gibson IW, et al. Biopsy-proven acute tubular necrosis in a child attributed to vancomycin intoxication[J]. Pediatr Nephrol, 2006, 21(8): 1194-1196. DOI: 10.1007/s00467-006-0152-0.

71.DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes[J]. Am J Kidney Dis, 1992, 20(4): 354-360. DOI: 10.1016/s0272-6386(12)70298-6.

72.Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit[J]. N Engl J Med, 2016, 375(2): 122-133. DOI: 10.1056/NEJ Moa1603017.

73.Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the elain randomized clinical trial[J]. JAMA, 2016, 315(20): 2190-2199. DOI: 10.1001/jama.2016.5828.